Increase in Yuflyma Prescriptions in Germany
Selected as Supplier by Ministry of Health Bidding Agency in Spain

Celltrion announced on January 30 that it has launched Aptozma (ingredient: tocilizumab), a treatment for autoimmune diseases, in major European countries including Germany, France, and Spain.


In France, the company secured the majority of supply volume through a private hospital group tender, accounting for approximately 80% of the private tocilizumab market in the country. Celltrion explained that it gained a competitive edge in the bidding process by emphasizing supply stability. In the retail market, the company is working to expand prescriptions by leveraging its established network of healthcare professionals, built through the sales of existing autoimmune disease treatments such as Remsima SC (ingredient: infliximab) and Yuflyma (ingredient: adalimumab).

Aptozyme product image. Celltrion

Aptozyme product image. Celltrion

View original image

Celltrion's French subsidiary also plans to conduct observational clinical studies to collect real-world prescription data. These studies, currently underway for Stekima (ingredient: ustekinumab) and Omriclo (ingredient: omalizumab), aim to evaluate the effects of switching to Aptozma and patient satisfaction. The company also intends to add Aidentzelt (ingredient: aflibercept) to these studies.


In Germany, Celltrion is focusing on expanding Aptozma sales through its local sales team. The company highlights the additional real-world safety data being collected for the intravenous formulation of Aptozma as a differentiating factor. Since the launch of Aptozma, prescriptions for Yuflyma, another autoimmune disease treatment, have also increased, resulting in a portfolio expansion effect.


In Spain, Celltrion has continued to win regional public tenders. The Spanish subsidiary secured supply contracts for Aptozma in key regions such as the Basque Country, Madrid, and Andalusia. It was also selected as a supplier in a tender organized by INGESA, a bidding agency under the Ministry of Health. In Spain, Celltrion launched a 400mg formulation that is not available in the original product.



A Celltrion representative stated, "With Aptozma, our fifth autoimmune disease treatment, successfully launched in major European countries, we plan to rapidly secure a leading position in the global tocilizumab market by leveraging the sales experience we have accumulated from our existing products," adding, "We will continue to strengthen our market dominance."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing